Jazz Pharmaceuticals (JAZZ) News Today

Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) has received several potentially important oncology updates, but the stock has decreased as investors weigh the commercial opportunity from Ziihera against financing-related dilution concerns and lower earnings forecasts.

• Positive Sentiment: FDA approval expands Ziihera’s addressable market. Jazz’s Ziihera (zanidatamab) won approval for first-line treatment of HER2-positive, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. The indication moves the drug into an earlier treatment setting and could materially strengthen Jazz’s oncology growth profile, supported by reported progression-free and overall-survival benefits. JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
• Positive Sentiment: Analysts remain constructive on JAZZ. Truist raised its price target to $281, while Needham and other analyst coverage highlighted potential for further appreciation. The targets imply continued confidence in Jazz’s earnings power and the potential contribution from Ziihera. Truist Financial Boosts Jazz Pharmaceuticals Price Target to $281
• Positive Sentiment: Companion-diagnostic expansion may support commercialization. Roche received expanded FDA approval for a diagnostic used to identify patients eligible for Jazz’s HER2-targeted cancer therapy, potentially improving testing and treatment access. Roche nabs expanded FDA approval for diagnostic tied to Jazz’s cancer drug
• Neutral Sentiment: Jazz upsized its debt offering while repurchasing shares. The company priced $1.1 billion of 1.875% exchangeable senior notes due 2032, up from $1.0 billion, alongside ordinary-share repurchases. Buybacks may support per-share results, but the larger financing increases leverage and introduces potential future dilution. Jazz Announces Pricing of Upsized Private Offering
• Negative Sentiment: Zacks reduced multiple forward EPS estimates. Cuts included FY2026 EPS to $20.77 from $21.72 and FY2027 EPS to $20.02 from $22.26, with additional quarterly reductions. Although FY2028 EPS remains projected at $22.74, the near- and medium-term revisions may pressure sentiment.